Analysts See $-0.79 EPS for Synlogic, Inc. (SYBX)

March 14, 2018 - By Richard Conner

 Analysts See $ 0.79 EPS for Synlogic, Inc. (SYBX)

Analysts expect Synlogic, Inc. (NASDAQ:SYBX) to report $-0.79 EPS on March, 21.They anticipate $2.15 EPS change or 73.13 % from last quarter’s $-2.94 EPS. After having $-1.66 EPS previously, Synlogic, Inc.’s analysts see -52.41 % EPS growth. The stock decreased 0.50% or $0.05 during the last trading session, reaching $10.03. About 54,035 shares traded. Synlogic, Inc. (NASDAQ:SYBX) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Synlogic, Inc. develops synthetic biotic medicines for the treatment of patients with urea cycle disorder and phenylketonuria. The company has market cap of $222.51 million.

Another recent and important Synlogic, Inc. (NASDAQ:SYBX) news was published by which published an article titled: “Synlogic: Precision-Programmed Probiotics To Treat Human Disease” on January 29, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: